Dar Bilaal Yousaf, Sahgal Gaayen Ravii, Jafar Tavgah, Jung Sangwoo R, Ahmad Mahmood, Providencia E Costa Rui Bebiano Da, Javid Iqra, Ahmad Syed Yousaf, Ahmad Malik Takreem, Yusuf Yusuf Abdirahman, Kashkosh Abdulrahman
Faculty of Life Sciences and Medicine, King's College London, Guy's Campus, Great Maze Pond, London SE1 1UL, UK.
Department of Psychiatry, University of Cambridge, Herchel Smith Building, Forvie Site, Robinson Way, Cambridge CB2 0SZ, UK.
Eur Heart J Open. 2025 Aug 21;5(5):oeaf103. doi: 10.1093/ehjopen/oeaf103. eCollection 2025 Sep.
Cardiogenic shock remains a significant cause of mortality despite multiple advancements in medical interventions. Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) provides crucial circulatory support but also increases left ventricular (LV) after-load, potentially worsening outcomes. Effective LV unloading strategies can enhance patient survival during VA-ECMO treatment. Our aim was to evaluate the impact of LV unloading strategies, including intra-aortic balloon pump (IABP) and Impella, on outcomes such as mortality and adverse effects in patients with cardiogenic shock treated with VA-ECMO.
A systematic search of EMBASE and Medline was conducted from inception up to 20 August 2024. Additional sources included forward citation searches of primary references. Inclusion criteria were studies reporting mortality rates in patients undergoing VA-ECMO with and without LV unloading. Exclusion criteria included case studies, editorials, commentaries, literature reviews, studies without a control group, those not examining LV unloading, studies on non-cardiogenic shock patients, and paediatric populations. From 943 identified studies, 26 met the inclusion criteria after abstract and full text screening by two authors. Data extraction followed PRISMA guidelines with independent reviewers abstracting data and assessing study quality using the Cochrane Risk of Bias in non-randomized studies (ROBINS-I) tool. A random-effects model was used to pool data, accounting for study heterogeneity. The primary outcome was all-cause mortality, assessed at three time points: intra-hospital mortality, 30-day mortality and mortality at longest available follow-up. Secondary outcomes included adverse effects such as bleeding, infection, cardiovascular events, limb ischaemia, and renal replacement therapy (RRT). The meta-analysis included 26 studies with a total of 22 625 patients. LV unloading strategies significantly reduced mortality compared to no unloading (RR: 0.80; 95% CI: 0.73 to 0.96). IABP (RR: 0.78; 95% CI: 0.69 to 0.89) was associated with a significant reduction of mortality compared to no unloading. All adverse effects were comparable across groups apart from significantly increased infection rates and need for RRT in Impella patients (RR: 1.37; 95% CI: 1.07 to 1.75, and RR: 2.02; 95% CI: 1.37 to 3.00, respectively).
LV unloading strategies associated with reduced mortality in patients with cardiogenic shock treated with VA-ECMO. Whilst adverse effects are similar across all strategies, Impella specifically is linked to higher infection rates and need for RRT. These findings could be used to support the use of LV unloading devices in clinical practice and highlight the need for further randomized controlled trials to establish optimal device-options and management protocols.
尽管医学干预取得了多项进展,但心源性休克仍是一个重要的死亡原因。静脉-动脉体外膜肺氧合(VA-ECMO)提供了关键的循环支持,但也增加了左心室(LV)后负荷,可能使预后恶化。有效的左心室减负策略可提高VA-ECMO治疗期间患者的生存率。我们的目的是评估左心室减负策略,包括主动脉内球囊反搏(IABP)和Impella,对接受VA-ECMO治疗的心源性休克患者的死亡率和不良反应等预后的影响。
对EMBASE和Medline从创刊至2024年8月20日进行了系统检索。其他来源包括对主要参考文献的正向引用检索。纳入标准为报告接受或未接受左心室减负的VA-ECMO患者死亡率的研究。排除标准包括病例研究、社论、评论、文献综述、无对照组的研究、未检查左心室减负的研究、非心源性休克患者的研究以及儿科人群研究。从943项已识别的研究中,经两位作者进行摘要和全文筛选后,26项符合纳入标准。数据提取遵循PRISMA指南,由独立评审员提取数据,并使用Cochrane非随机研究偏倚风险(ROBINS-I)工具评估研究质量。采用随机效应模型汇总数据,考虑研究的异质性。主要结局是全因死亡率,在三个时间点进行评估:院内死亡率、30天死亡率以及最长可用随访期的死亡率。次要结局包括不良反应,如出血、感染、心血管事件、肢体缺血和肾脏替代治疗(RRT)。荟萃分析纳入了26项研究,共22625例患者。与未减负相比,左心室减负策略显著降低了死亡率(RR:0.80;95%CI:0.73至0.96)。与未减负相比,IABP(RR:0.78;95%CI:0.69至0.89)与死亡率显著降低相关。除了Impella患者的感染率显著增加和RRT需求增加外(RR分别为:1.37;95%CI:1.07至1.75,以及RR:2.02;95%CI:1.37至3.00),各亚组的所有不良反应均具有可比性。
在接受VA-ECMO治疗的心源性休克患者中,左心室减负策略与死亡率降低相关。虽然所有策略的不良反应相似,但Impella特别与较高的感染率和RRT需求相关。这些发现可用于支持在临床实践中使用左心室减负装置,并强调需要进一步进行随机对照试验以确定最佳的装置选择和管理方案。